{"id":34625,"date":"2025-06-03T17:57:19","date_gmt":"2025-06-03T09:57:19","guid":{"rendered":"https:\/\/flcube.com\/?p=34625"},"modified":"2025-06-03T17:57:20","modified_gmt":"2025-06-03T09:57:20","slug":"cspc-pharmaceuticals-jmt101-receives-breakthrough-therapy-designation-for-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34625","title":{"rendered":"CSPC Pharmaceutical&#8217;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer"},"content":{"rendered":"\n<p>China-based CSPC Pharmaceutical Group Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China&#8217;s Center for Drug Evaluation (CDE). This designation highlights the drug&#8217;s potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.<\/p>\n\n\n\n<p><strong>JMT101 Clinical Performance<\/strong><br>JMT101, an anti-EGFR monoclonal antibody (mAb) with ADCC and CDC effects, demonstrated superior outcomes when combined with irinotecan in a Phase II trial. It achieved a median progression-free survival (mPFS) of 7.4 months, compared to 2.9 months in the control group. The drug also showed improvements in objective response rate (ORR) and disease control rate (DCR).<\/p>\n\n\n\n<p><strong>Colorectal Cancer in China<\/strong><br>Colorectal cancer is the second most common malignant tumor in China, with 517,000 new cases and 240,000 deaths reported in 2022. The limited efficacy of standard treatment regimens for advanced patients underscores the significant unmet clinical need. JMT101&#8217;s breakthrough therapy designation reflects its potential to address this critical demand.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060202977_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025060202977_c.\"><\/object><a id=\"wp-block-file--media-afd131ce-22f1-4986-a919-797d5417691f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060202977_c.pdf\">2025060202977_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/2025060202977_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-afd131ce-22f1-4986-a919-797d5417691f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34626,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,171,855,15],"class_list":["post-34625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-cspc-pharmaceutical","tag-hkg-1093","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical&#039;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China&#039;s Center for Drug Evaluation (CDE). This designation highlights the drug&#039;s potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical&#039;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer\" \/>\n<meta property=\"og:description\" content=\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China&#039;s Center for Drug Evaluation (CDE). This designation highlights the drug&#039;s potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34625\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T09:57:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T09:57:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical&#8217;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer\",\"datePublished\":\"2025-06-03T09:57:19+00:00\",\"dateModified\":\"2025-06-03T09:57:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0315.webp\",\"keywords\":[\"Cancer\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34625#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34625\",\"name\":\"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0315.webp\",\"datePublished\":\"2025-06-03T09:57:19+00:00\",\"dateModified\":\"2025-06-03T09:57:20+00:00\",\"description\":\"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China's Center for Drug Evaluation (CDE). This designation highlights the drug's potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34625\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0315.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0315.webp\",\"width\":1080,\"height\":608,\"caption\":\"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical&#8217;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China's Center for Drug Evaluation (CDE). This designation highlights the drug's potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34625","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer","og_description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China's Center for Drug Evaluation (CDE). This designation highlights the drug's potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.","og_url":"https:\/\/flcube.com\/?p=34625","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T09:57:19+00:00","article_modified_time":"2025-06-03T09:57:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34625#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34625"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical&#8217;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer","datePublished":"2025-06-03T09:57:19+00:00","dateModified":"2025-06-03T09:57:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34625"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","keywords":["Cancer","CSPC Pharmaceutical","HKG: 1093","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34625#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34625","url":"https:\/\/flcube.com\/?p=34625","name":"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34625#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34625#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","datePublished":"2025-06-03T09:57:19+00:00","dateModified":"2025-06-03T09:57:20+00:00","description":"China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its JMT101 has been awarded breakthrough therapy designation (BTD) by China's Center for Drug Evaluation (CDE). This designation highlights the drug's potential as a treatment for wild-type advanced colorectal cancer (CRC) patients with RAS, RAF, EGFR ECD, and PIK3CA 20 exons who have failed second-line or above standard treatment, in combination with irinotecan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34625"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34625#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","width":1080,"height":608,"caption":"CSPC Pharmaceutical's JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical&#8217;s JMT101 Receives Breakthrough Therapy Designation for Colorectal Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0315.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34625"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34625\/revisions"}],"predecessor-version":[{"id":34628,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34625\/revisions\/34628"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34626"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}